Amicus Therapeutics Files 8-K on Jan 7 Event; Signals Corporate Communications

Ticker: FOLD · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1178879

Amicus Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAmicus Therapeutics, Inc. (FOLD)
Form Type8-K
Filed DateJan 8, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: corporate-action, regulatory-filing, communication

TL;DR

**Amicus Therapeutics filed an 8-K on Jan 7, signaling potential major corporate communications.**

AI Summary

Amicus Therapeutics, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 7, 2024. This filing indicates that the company is making a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically checking boxes for written communications under Rule 425 and soliciting material under Rule 14a-12. For investors, this matters because it signals that Amicus Therapeutics is actively engaging in communications that could relate to significant corporate actions, potentially impacting the stock's future valuation or ownership structure.

Why It Matters

This filing indicates Amicus Therapeutics is engaging in specific corporate communications, which could precede or relate to important business developments like mergers, acquisitions, or significant financial updates, directly affecting shareholder value.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the checked boxes for Rule 425 and Rule 14a-12 suggest upcoming or ongoing significant corporate actions, which inherently carry both opportunities and risks for investors.

Analyst Insight

Investors should monitor Amicus Therapeutics' subsequent filings and press releases closely for specific details related to the corporate communications indicated by the Rule 425 and Rule 14a-12 checks, as these could signal significant strategic changes or transactions.

Key Numbers

  • $0.01 — Par Value (Par value of Amicus Therapeutics' Common Stock)

Key Players & Entities

  • AMICUS THERAPEUTICS, INC. (company) — the registrant filing the 8-K
  • January 7, 2024 (date) — date of the earliest event reported
  • January 8, 2024 (date) — date the 8-K was filed
  • Rule 425 (other) — Securities Act rule for written communications
  • Rule 14a-12 (other) — Exchange Act rule for soliciting material
  • Nasdaq (other) — exchange where Common Stock Par Value $0.01 is registered
  • FOLD (other) — trading symbol for Amicus Therapeutics

Forward-Looking Statements

  • Amicus Therapeutics will release further details regarding the corporate communications hinted at by the Rule 425 and Rule 14a-12 checks. (AMICUS THERAPEUTICS, INC.) — medium confidence, target: Q1 2024

FAQ

What was the earliest event reported in this 8-K filing by Amicus Therapeutics, Inc.?

The earliest event reported in this 8-K filing by Amicus Therapeutics, Inc. occurred on January 7, 2024.

Under which specific rules did Amicus Therapeutics, Inc. indicate this 8-K filing is intended to satisfy filing obligations?

Amicus Therapeutics, Inc. indicated this 8-K filing is intended to simultaneously satisfy filing obligations under Rule 425 of the Securities Act (17 CFR 230.425) and Rule 14a-12 of the Exchange Act (17 CFR 240.14a-12).

What is the trading symbol and the exchange where Amicus Therapeutics, Inc.'s common stock is registered?

Amicus Therapeutics, Inc.'s common stock has the trading symbol FOLD and is registered on Nasdaq.

What is the par value of the common stock mentioned in the filing?

The par value of the common stock mentioned in the filing is $0.01.

What is the business address and phone number listed for Amicus Therapeutics, Inc. in this filing?

The business address for Amicus Therapeutics, Inc. is 47 Hulfish Street, Princeton, New Jersey 08542, and the business phone number is 609-662-2000.

Filing Stats: 565 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-01-08 07:01:02

Key Financial Figures

  • $0.01 — ich registered Common Stock Par Value $0.01 FOLD Nasdaq Indicate by check mar

Filing Documents

02 – Results of Operations and Financial

Item 2.02 – Results of Operations and Financial Condition. On January 7, 2024, Amicus Therapeutics, Inc. (the "Company") issued a press release announcing preliminary 2023 revenue and its 2024 strategic outlook, along with various business updates. A copy of the press release is attached hereto as Exhibit 99.1. As previously announced, the Company will also be presenting at the 42 nd Annual J.P. Morgan Healthcare Conference on January 8 th , 2024. A copy of the presentation materials management will be using at the conference is also attached hereto as Exhibit 99.2. Both exhibits are incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release dated January 7, 2024 99.2 Presentation Materials – 42 nd Annual J.P. Morgan Healthcare Conference 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Signature Page Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMICUS THERAPEUTICS, INC. Date: January 8, 2024 By: /s/ Ellen S. Rosenberg Name: Ellen S. Rosenberg Title: Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.